Home›Trial›NCT05918692
🔬NCT05918692Phase 1ACTIVE NOT RECRUITING

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

Study Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

Conditions
Acute Myeloid Leukemia
Interventions / Drugs
BMF-500
View on ClinicalTrials.gov ↗
Sponsor
BMEA
Biomea Fusion
Covalent Small Molecules
D39/100
Study Details
Enrollment35 participants
Primary Completion—
Lead SponsorBiomea Fusion Inc.
Data Retrieved2026-04-11 04:08:06.413410+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.